Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Adenomatous Polyp of Colon
- Colo-rectal Cancer
- Polyp of Colon
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The details of the proposed study are as follows: Experimental group: using EverLift submucosal injection for polyps 4-9mm of the colon Control group: not using EverLift submucosal injection for polyps 4-9mm of the colon Methods: Colonoscopy will be performed in the same standard of care manner as i...
The details of the proposed study are as follows: Experimental group: using EverLift submucosal injection for polyps 4-9mm of the colon Control group: not using EverLift submucosal injection for polyps 4-9mm of the colon Methods: Colonoscopy will be performed in the same standard of care manner as if no study was taking place. If polyps 4-9mm are identified, the endoscopist is randomized to performing polypectomy with or without submucosal injection of EverLift. After removal of the polypectomy, two biopsies are performed at the margin of the polypectomy site to identify residual lesion. The polyp as well as well as the two biopsies are reviewed by a pathologist.
Tracking Information
- NCT #
- NCT04551014
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Shai Friedland, MD Stanford University
Get Well Soon